Cogstate Ltd (ASX:CGS)

Half Year 2025 CogState Ltd Earnings Call Transcript

Feb 19, 2025 / 10:00 PM GMT

Release Date Price: A$1.24

Transcript

Key Points

Positve

Cogstate Ltd (COGZF) reported a record revenue result for the first half of the 2025 financial year, with total revenue of $23.9 million, up 19% from the previous corresponding period.
The company achieved a significant improvement in gross profit margin, up 2.5 points from the most recent half and 7 points compared to the previous corresponding period.
Profit before tax increased by 150% compared to the previous corresponding period, driven by strong growth in clinical trials revenue and excellent cost control.
Cogstate Ltd (COGZF) has established a promising partnership with Medidata, which has already resulted in a phase 2 influenza trial award and a strong initial pipeline of opportunities.
The company has made significant investments in technology, leading to efficiency gains through automation in data analytics, data management, and workflow management, positioning it well for future growth.

Negative

Despite the record revenue, the value of contracted future clinical trials revenue decreased by 8% due to higher revenue recognition than sales contracts executed.
Contracted future healthcare revenue also reduced as a result of the amendment of the ASI agreement, leading to a 20% decrease in total contracted future revenue compared to the previous year.
Healthcare revenue saw a decline due to the renegotiation of the healthcare license agreement with AI, resulting in a reduction of future receipts by approximately $15 million.
The number of employees decreased from 166 to 154, indicating a reduction in workforce, which could impact operational capacity.
Operating expenses increased by $0.8 million due to ongoing investments in advanced analytics and automated data analysis, which could pressure short-term profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CGS.AX - CogState Ltd
Half Year 2025 CogState Ltd Earnings Call
Feb 19, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello everyone, and thank you so much for joining us today for this half year financial results from the 2025 financial year. We're going to go ahead and just jump right over and we'll have Brad get started with the numbers. We'll also be hearing from Darren Watson, our Chief Financial Officer here at Cog State, as well as Rachel Kolle, who is our executive Vice President of clinical trials. But first, over to Brad.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Ruth. Welcome everybody. I'm really pleased to, present the half year financial results for cogsto, for the 6 months at

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.